Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14294261 | 0.80 | RAB9A (0.48) | MGLLLMNACYP17A1 | |
| SCHEMBL3097068 | 0.76 | ACMSD (0.51) | — | |
| SCHEMBL22926337 | 0.76 | TSHR (0.43) | KDM4E | |
| SCHEMBL11150735 | 0.76 | ESR2 (0.53) | ESR2HSD17B1 | |
| SCHEMBL9150363 | 0.76 | KDM4E (0.71) | ESR1ESR2MGLLKDM4ELMNA | |
| SCHEMBL14270103 | 0.76 | ESR2 (0.51) | ESR1ESR2MGLLKDM4ELMNA | |
| SCHEMBL13609860 | 0.75 | HSD17B1 (0.52) | ESR1ESR2HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL857363 | 0.74 | ESR1 (0.68) | ESR1ESR2MGLLKDM4ELMNA | |
| SCHEMBL30635318 | 0.74 | ESR1 (0.68) | ESR1ESR2MGLLKDM4ELMNA | |
| SCHEMBL28683577 | 0.74 | KDM4E (0.68) | ESR1ESR2MGLLKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | ESR1, ESR2, ESRRB | ESR1 1/4885ESR2 2/4885MGLL 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.